Mitochondrial and Energy Support
Given the evidence for energy metabolism dysfunction in ME/CFS (Chapter Energy Metabolism and Mitochondrial Function), supplements supporting mitochondrial function are among the most commonly used.
1 Coenzyme Q10 (CoQ10/Ubiquinone/Ubiquinol)
Rationale. CoQ10 is a mobile electron carrier in the electron transport chain, shuttling electrons from Complex I and Complex II to Complex III, and is a potent lipid-soluble antioxidant.
Evidence. Moderate. Multiple small studies show benefit in ME/CFS (Maes et al. 2009) (Castro-Marrero 2015: n=73, CoQ10+NADH combination) and fibromyalgia (Cordero et al. 2013). A 2022 systematic review and meta-analysis of 13 RCTs (n=1,126) found CoQ10 significantly reduced fatigue across several chronic conditions (cancer fatigue, MS, fibromyalgia, cardiovascular disease; not ME/CFS-specific) (Tsai et al. 2022). In a large patient-reported survey (\(n = 3{,}925\)), higher CoQ10 doses strongly outperformed lower doses: positive response 50.7% at >200 mg/day versus 26.7% at 50–100 mg/day (Eckey et al. 2025) — a real-world dose-response signal consistent with the Tsai 2022 meta-analysis coefficient and with the dosing table below. (Severity applicability: unknown — survey did not stratify by severity.)
The Tsai 2022 meta-analysis provides high-quality evidence that CoQ10 reduces fatigue across multiple chronic conditions. The dose-response relationship (coefficient = -0.0017 per mg, p < 0.001) and duration-response relationship (coefficient = -0.0042 per day, p = 0.007) enable evidence-based dosing decisions. CoQ10-only formulations were more effective than CoQ10 compounds in the analysis.
- Ubiquinol: Reduced (active) form; better absorbed, especially over age 40; more expensive
Dosing.
- Typical: 100–300 mg daily
- Higher doses in studies: 400–600 mg daily
- Take with fat-containing meal for absorption
- Split doses if \(\\>\) 200 mg
Response Timeline. Benefits may take 4–12 weeks to manifest.
Cautions. Generally well-tolerated. May reduce warfarin effectiveness (see Section D-Ribose Evidence Quality, drug interactions). Can cause insomnia if taken late in day (clinical observation).
Energy Profile. Category A (net energy provider). Functions as a mobile electron carrier in the ETC (see Rationale above). See Chapter Medications Targeting Underlying Mechanisms for detailed energy profile.
2 NADH (Reduced Nicotinamide Adenine Dinucleotide)
Rationale. NADH is the reduced form of NAD+ and serves as the primary electron donor to Complex I (NADH dehydrogenase) of the mitochondrial electron transport chain. Supplementing NADH directly provides electrons for ATP synthesis, complementing CoQ10 which shuttles electrons between complexes. Together, NADH and CoQ10 support electron supply at two distinct points in the proximal electron transport chain.
Evidence. Low–Moderate (Low for NADH monotherapy; Moderate for the NADH+CoQ10 combination).
- Forsyth et al. (1999) (Forsyth et al. 1999): Randomized, double-blind, placebo-controlled crossover trial (n=26); 10 mg NADH daily for 4 weeks showed 31% response rate vs. 8% placebo
- Santaella et al. (2004) (Santaella, Font, and Disdier 2004): Randomized trial (n=31, no placebo arm) comparing NADH to an active control (nutritional supplements plus psychotherapy) over 24 months; significant improvement in the NADH group in the first three months (\(p \\< 0.001\) vs. control), but outcomes later comparable between groups
- Castro-Marrero et al. (2016) (Castro-Marrero et al. 2016): RCT (n=80); CoQ10 (200 mg) + NADH (20 mg) improved maximum heart rate recovery; some improvement in fatigue perception, though fatigue effects were inconsistent across the broader program of trials
- Castro-Marrero et al. (2021) (Castro-Marrero et al. 2021): Largest RCT to date (n=207, double-blind, placebo-controlled); 200 mg CoQ10 + 20 mg NADH daily for 12 weeks showed significant improvements in cognitive fatigue (\(p \\< 0.001\)), overall fatigue (\(p = 0.022\)), quality of life (\(p \\< 0.05\)), and sleep parameters (sleep duration at week 4, \(p = 0.018\); sleep efficiency at week 8, \(p = 0.038\)). Benefits persisted 4 weeks post-treatment. No serious adverse events
The Castro-Marrero 2021 trial provides the strongest evidence for the NADH+CoQ10 combination in ME/CFS. It does not, however, distinguish the individual contribution of NADH from that of CoQ10. See Section D-Ribose Evidence Quality for combination rationale.
Forms.
- Enteric-coated tablets: Protect against gastric acid degradation; most common form
- Sublingual: Bypasses gastric degradation; may provide faster absorption
- Enada: Brand used in multiple clinical trials; standardized formulation
Dosing.
- Standard: 10–20 mg daily
- Clinical trial dose: 20 mg daily (Castro-Marrero protocol)
- Must be taken on an empty stomach, 30–60 minutes before breakfast (gastric acid degrades unprotected NADH)
Response Timeline. 4–8 weeks for monotherapy; combination with CoQ10 may show benefits within 4 weeks for sleep parameters.
Cautions. Generally well-tolerated. Unprotected oral NADH is degraded by stomach acid—use enteric-coated or sublingual forms only. Some patients report mild nausea if taken with food. Cost is moderate ($20–40/month at therapeutic doses).
NADH vs. NAD+ Precursors. NADH and NAD+ precursors (NR, NMN) are complementary, not interchangeable—they target different axes of cellular energy metabolism. See Section D-Ribose Evidence Quality for the full two-axis framework and combination recommendations.
Energy Profile. Category A (net energy provider). Direct electron donor to Complex I; each NADH molecule reaching the mitochondrial matrix yields approximately 2.5 ATP via oxidative phosphorylation. Oral bioavailability is a limiting factor (see Forms above).
3 NAD+ Precursors: Nicotinamide Riboside (NR) and NMN
Rationale. NAD+ is essential for mitochondrial function, DNA repair, and cellular signaling. The Heng 2025 study (Heng et al. 2025) documented NAD+ metabolism abnormalities in ME/CFS. While direct oral NAD+ supplementation has poor bioavailability (gastric degradation), sublingual NAD+ (100–300 mg/day) offers a direct route, and precursors efficiently raise intracellular levels. NAD+ precursors replenish the cellular NAD+ pool for sirtuins and PARP-mediated DNA repair—a complementary mechanism to the direct electron donation provided by NADH (Section Strong Meta-Analysis Evidence Base). For combination guidance, see Section D-Ribose Evidence Quality.
Evidence. Preliminary. A 2025 RCT in Long COVID (n=58; 20-week intervention) showed NR 2000 mg/day increased whole-blood NAD+ levels 2.6–3.1 fold (measured at interim timepoints of 5 and 10 weeks); cognitive benefits were variable, with overall group effects limited but some individuals showing improvement after \(\geq\) 10 weeks (Wu, Guzmán-Vélez, et al. 2025). Important caveat: The Wu 2025 trial is cited here for whole-blood NAD+ elevation (a robust surrogate); its null primary cognitive endpoint means it does not support efficacy claims. Whole-blood NAD+ does not equal tissue-level NAD+: human RCTs show NR robustly elevates blood NAD+ but produces small or undetectable NAD+ rises in muscle tissue (unreplicated in brain). In inflammatory states, CD38 (NADase) is upregulated and may consume NR-derived NAD+ before SIRT1 can access it. Nicotinamide (a metabolic byproduct of NR/NMN) inhibits sirtuins at high intracellular concentrations, potentially limiting the SIRT1 restoration mechanism. These barriers are relevant to interpreting the NR/NMN-HSAT2 speculation below and to setting realistic expectations for clinical response.
Forms.
- Nicotinamide Riboside (NR): Tru Niagen is the most studied brand
- Nicotinamide Mononucleotide (NMN): One step closer to NAD+; theoretically more direct but less clinical data
- Niacin (B3): Cheapest NAD+ precursor but causes flushing; extended-release reduces flushing but has liver toxicity concerns
- Nicotinamide: No flushing; inhibits sirtuins via product inhibition at high concentrations (well-established in vitro (Bitterman et al. 2002); clinical relevance at oral supplementation doses uncertain)
- NAD+ sublingual: Direct NAD+ administered under the tongue (100–300 mg/day); bypasses gastric degradation but bioavailability data remain limited. Substitutable with NR or NMN—choose one precursor strategy
Dosing.
- NR: 300–1000 mg daily typical; research doses up to 2000 mg
- NMN: 250–500 mg daily typical; up to 1000 mg in some regimens
- NAD+ sublingual: 100–300 mg daily
- Niacin: 500–1500 mg daily (with caution)
Emergency Use (Speculative). For emergency post-exertion PEM prevention, high-dose loading (1000–2000 mg NR or NMN immediately post-exertion, then 500 mg twice daily for 3–5 days) may prevent NAD+ depletion hypothetically attributable to PARP activation during DNA repair—this mechanism is plausible but unconfirmed in ME/CFS specifically (Dehhaghi et al. 2022). Caution: This protocol has not been tested in any clinical trial. High-dose NR/NMN may cause gastrointestinal side effects and has not been safety-tested at these doses in ME/CFS patients. Discuss with physician before attempting. See Chapter Emerging and Investigational Therapies,:pem-prevention for complete emergency protocol.
Response Timeline. May require 10+ weeks for noticeable benefit.
Cost Consideration. NR/NMN are expensive ($50–150/month at therapeutic doses). Niacin is cheap but has tolerability issues.
Cautions. Generally well-tolerated at standard doses. Gastrointestinal discomfort may occur at high doses (\(\geq\) 1000 mg). Theoretical concern: elevated NAD+ may promote tumor growth in active cancer—rapidly proliferating cells may exploit NAD+ for energy and DNA repair (Palmer and Vaccarezza 2021). Avoid during active cancer; consult oncologist before use in patients with cancer history. Extended-release niacin carries hepatotoxicity risk (see Section D-Ribose Evidence Quality).
Energy Profile. Category A (net energy provider). Replenish cellular NAD+ pools required for hundreds of metabolic reactions including glycolysis, TCA cycle, and oxidative phosphorylation. Conversion from NR/NMN to NAD+ requires minimal ATP (one phosphorylation step). Net energy balance strongly positive. Emergency high-dose protocols (see Emergency Use above) are hypothesized to provide immediate NAD+ substrate for PARP-mediated DNA repair (Dehhaghi et al. 2022)—this rationale is mechanistically plausible but not yet confirmed in ME/CFS trials.
4 D-Ribose
Rationale. D-ribose is the pentose sugar component of ATP. Supplementation may accelerate ATP resynthesis after depletion.
Evidence. Low. A pilot open-label study (n=41) (Jacob E. Teitelbaum, Johnson, and St Cyr 2006) and a larger multicenter replication (n=257; \(p \\< 0.0001\) within-group for energy, sleep, and well-being) (J. E. Teitelbaum et al. 2012) in ME/CFS and fibromyalgia showed improvements with 5 g three times daily; no placebo comparison in either study, so results cannot be distinguished from placebo effect.
Teitelbaum 2006/2012: within-group only, no placebo arm, supplement industry co-authorship; the p-value reflects pre/post change without controlling for regression-to-mean or expectation effects. Treat as hypothesis-generating only.
Dosing. 5 g three times daily (15 g/day total); can be reduced to 5–10 g daily for maintenance.
Emergency Use. For emergency post-exertion PEM prevention, higher acute doses (10–15 g immediately post-exertion, then 5 g every 4–6 hours for 24–48h) may be used as part of comprehensive crash prevention protocol. See Chapter Emerging and Investigational Therapies,:pem-prevention for complete emergency protocol.
Practical Tips.
- Take with meals (can lower blood sugar)
- Sweet taste; dissolves in beverages
- Some patients report energy improvement within days
Cautions. May lower blood sugar; diabetics should monitor carefully.
Energy Profile. Category A (net energy provider). Direct ATP substrate (pentose sugar component). May reduce reliance on the energy-intensive pentose phosphate pathway by entering purine salvage directly (Dodd, Johnson, and St Cyr 2004). Among the most direct energy substrates available—minimal metabolic processing required for ATP regeneration.
5 Acetyl-L-Carnitine (ALCAR) and L-Carnitine
Rationale. Carnitine transports fatty acids into mitochondria for oxidation. Deficiency impairs fat-based energy production. Acetyl-L-carnitine crosses the blood-brain barrier and may support cognitive function.
Evidence. Low (open-label studies only; no placebo-controlled trials). CFS patients show lower serum carnitine levels correlating with functional capacity (Plioplys and Plioplys 1995). L-carnitine 3 g/day improved 12 of 18 clinical parameters over 8 weeks (n=30, open-label) (Plioplys and Plioplys 1997). Acetyl-L-carnitine improved mental fatigue (\(p = 0.015\)) and propionyl-L-carnitine improved general fatigue (\(p = 0.004\)) in an open-label randomized study (n=90, no placebo arm) (Vermeulen and Scholte 2004).
Forms.
- L-Carnitine: General mitochondrial support
- Acetyl-L-Carnitine (ALCAR): Better for cognitive symptoms; crosses BBB
- Propionyl-L-Carnitine: May be better for cardiovascular symptoms
Dosing. 500–2000 mg daily; split doses.
Response Timeline. 2–8 weeks.
Cautions. Can increase TMAO (a proposed cardiovascular risk marker) with chronic use; the mechanism—gut microbial conversion of carnitine to trimethylamine, then hepatic oxidation to TMAO—is documented in published literature, though the clinical significance for cardiovascular risk remains debated. Some patients experience overstimulation or insomnia. L-carnitine may theoretically lower seizure threshold in patients with pre-existing epilepsy based on mechanistic considerations; consult physician before use in seizure disorders (no controlled data; clinical caution).
Energy Profile. Category A (net energy provider). Enables mitochondrial fatty acid oxidation—the most energy-dense metabolic pathway. Each fatty acid molecule transported into mitochondria by carnitine yields substantially more ATP than glucose oxidation. Processing overhead negligible relative to energy yield.
6 Creatine
Rationale. Creatine buffers ATP, providing rapid energy during high-demand situations. Well-studied for muscle function; emerging evidence for cognitive benefits.
Evidence. Theoretical for ME/CFS; strong for lower limb muscle strength in general populations (meta-analysis) (Lanhers et al. 2015). Emerging evidence for cognitive benefits under stress—sleep deprivation, mental fatigue—in general populations (small RCTs; no ME/CFS-specific data).
Dosing.
- Loading (optional): 5 g four times daily for 5–7 days. Note: the loading phase is derived from sports nutrition protocols; ME/CFS patients may prefer to skip loading and start directly at maintenance doses, consistent with conservative introduction (Section Practical Supplement Protocols)
- Maintenance: 3–5 g daily
Cautions. Requires adequate hydration. May cause water retention. Generally considered safe for kidney function in healthy individuals at normal doses (no controlled evidence of harm; serum creatinine elevation reflects creatine metabolism, not renal impairment—see Additional interactions below).
Energy Profile. Category A (net energy provider). Directly buffers ATP via the phosphocreatine system—the fastest cellular energy reserve. Creatine kinase converts phosphocreatine to ATP within milliseconds, providing immediate energy during demand spikes. Also supports brain energy metabolism. Minimal processing demands.
Architecture C: Cognitive PEM Buffer. In the metabolic reserve framework (Architectural Uncertainty: Architecture A Cannot Be Ruled Out), creatine monohydrate maintains a phosphocreatine reserve that regenerates ATP faster than mitochondrial oxidative phosphorylation. In a brain with reduced \(R_\text{headroom}\), phosphocreatine acts as a temporal buffer — extending the window during which cognitive demand can exceed mitochondrial production capacity before ATP depletion triggers the damage cascade. The analogy: if mitochondrial capacity is the generator and ATP the electricity, phosphocreatine is the battery backup. A smaller generator (neurodivergent brain) benefits MORE from a larger battery than a large generator does. Brain creatine supplementation (5 g/day for 6 weeks) improves working memory and processing speed in healthy adults (multiple RCTs). No ME/CFS-specific trials exist, but at ~$0.50/day with extensive safety data, creatine is among the most actionable Architecture C interventions. (Certainty: 0.35.)
7 PQQ (Pyrroloquinoline Quinone)
Rationale. PQQ stimulates mitochondrial biogenesis (creation of new mitochondria) and has antioxidant properties.
Evidence. Preliminary. Small RCTs in healthy adults show cognitive benefits: improved attention and working memory with 20 mg/day over 12 weeks (Tamakoshi et al. 2023); no ME/CFS-specific trials.
Dosing. 10–20 mg daily.
Energy Profile. Category A (indirect; delayed onset: weeks to months). Net energy provider through mitochondrial biogenesis rather than direct substrate supply. Stimulates the creation of new mitochondria, increasing total cellular energy production capacity over weeks to months. Unlike CoQ10 or NADH, PQQ does not directly participate in electron transport—its energy benefit is mediated entirely through expanding mitochondrial mass. Do not expect acute energy improvement.
8 Mitochondrial Energy Support: Combination Guide
The supplements in this section target distinct steps in cellular energy production. Understanding which ones are complementary and which are substitutable prevents both redundant spending and missed synergies.
8.1 Two Complementary Axes
Mitochondrial energy supplements can be organized into two mechanistically distinct axes. This framework is a conceptual model for understanding supplement complementarity; the empirical support comes from the Castro-Marrero trials, not from the framework itself.
Axis 1: Electron Transport Chain Support (NADH + CoQ10). NADH donates electrons to Complex I; CoQ10 shuttles electrons from Complex I and Complex II to Complex III. Together they support electron supply at two distinct points in the proximal ETC. The Castro-Marrero 2021 RCT (n=207) used exactly this combination—200 mg CoQ10 + 20 mg NADH—and demonstrated significant improvements in fatigue, cognition, and sleep parameters (Castro-Marrero et al. 2021). These two supplements form a functional pair and should be taken together.
Axis 2: NAD+ Pool Replenishment (choose one precursor). NR, NMN, and sublingual NAD+ all aim to increase intracellular NAD+ levels, supporting sirtuins (cellular stress response), PARP (DNA repair), and metabolic signaling. Because they converge on the same endpoint, one should be chosen based on evidence, tolerability, and cost. NR and NMN are the best-supported options and are largely interchangeable for this purpose:
- NR: Most clinical data; well-absorbed; Tru Niagen brand used in trials
- NMN: One enzymatic step closer to NAD+; popular but fewer published RCTs.[^1]
- NAD+ sublingual: Direct delivery; limited bioavailability data; cannot be considered fully equivalent to NR or NMN until absorption is better characterized
Niacin and nicotinamide are also NAD+ precursors but are not recommended for Axis 2: niacin causes flushing and carries hepatotoxicity risk at extended-release doses, while nicotinamide inhibits sirtuins at high concentrations (well-established in vitro; see Forms above)—directly counteracting one of Axis 2’s intended benefits.
These two axes are complementary, not redundant. After donating electrons at Complex I, NADH is oxidized back to NAD+, so it does contribute to the mitochondrial NAD+ pool. However, supplemental NADH doses are modest (10–20 mg, approximately 15–30 \(\mu\)mol), while total body NAD+ content is estimated at 1–3 g (approximately 1,500–4,500 \(\mu\)mol; estimate based on tissue concentration measurements (Massudi et al. 2012))—dwarfing the contribution from a single NADH dose. NADH’s primary pharmacological action is therefore acute electron donation, not sustained NAD+ pool elevation. NAD+ precursors (NR, NMN) act through the salvage pathway to raise NAD+ levels across all cellular compartments—cytosolic, nuclear, and mitochondrial—at much larger scale. Thus, Axis 1 provides the electrons that drive ATP synthesis now, while Axis 2 replenishes the coenzyme pool that sustains energy metabolism, DNA repair, and cellular signaling over time.
8.2 Age-Stratified Dosing
Pediatric dosing for mitochondrial supplements is extrapolated from adult data and body-weight scaling, not from pediatric randomized controlled trials. No ME/CFS-specific supplement trials have been conducted in children or adolescents. All pediatric use should be under physician supervision, with conservative starting doses and careful monitoring.
| Supplement | Adults (\(\geq\) 18y) | Adolescents (12–17y) | Children (6–11y) | Notes |
|---|---|---|---|---|
| NADH | 10–20mg | 5–10mg | Not recommended | Empty stomach, 30min before breakfast |
| CoQ10 (ubiquinol) | 100–300mg | 50–100mg | 25–50mg | With fat-containing meal; RCT dose 200mg |
| NR | 300–1000mg | 150–250mg | Not recommended | 300–500mg starting; research doses up to 2000mg |
| NMN | 250–500mg | 125–250mg | Not recommended | Choose one NAD+ precursor |
| NAD+ sublingual | 100–300mg | Not recommended | Not recommended | Limited safety data |
| D-Ribose | 5–15g | 3–5g | 1–3g | With meals; may lower blood sugar |
| ALCAR | 500–2000mg | 250–500mg | Not recommended | Split doses; may cause insomnia |
| Creatine | 3–5g | 2–3g | 1–2g | Adequate hydration essential |
| PQQ | 10–20mg | 10mg | Not recommended | Preliminary evidence only |
8.3 Recommended Combinations
Three evidence-informed combination tiers, using the two-axis framework above as an organizational heuristic; only the Minimal tier has direct RCT support. Use age-appropriate doses from Table Pediatric Evidence Gap. For children under 12, where NADH is not recommended, the Minimal tier reduces to CoQ10 alone.
Minimal (the Castro-Marrero protocol). NADH + CoQ10. This is the only combination tested in a large ME/CFS RCT (Castro-Marrero et al. 2021). Start here.
Standard. NADH + CoQ10 + one NAD+ precursor (NR or NMN). Adds Axis 2 support for the cellular NAD+ pool. NR has the most clinical data; NMN is a reasonable alternative.
Comprehensive. NADH + CoQ10 + one NAD+ precursor + D-ribose + ALCAR. Adds ATP substrate (D-ribose) and fatty acid transport into mitochondria (carnitine). Higher cost; consider adding components one at a time to assess individual benefit.
8.4 What Not to Combine
Redundant combinations (not dangerous, but wasteful).
- Multiple NAD+ precursors at full dose: Taking NR 500 mg + NMN 500 mg + NAD+ sublingual 300 mg simultaneously provides no proportional benefit over a single precursor—they all converge on the same intracellular NAD+ pool. Because NR and NMN differ in molecular weight, a simple 50/50 mg split does not achieve equal molar doses—the simplest approach is to choose one precursor and use it at full dose
- High-dose niacin alongside NR or NMN: Niacin is also an NAD+ precursor; stacking it with NR/NMN adds flushing risk without clear additional benefit
- CoQ10 + warfarin: CoQ10 may reduce warfarin effectiveness—the mechanism may involve enhanced CYP450-mediated warfarin hydroxylation (Zhou, Zhou, and Chan 2005); a structural similarity to vitamin K has also been proposed but is less well-documented. Monitor INR closely if combining; adjust warfarin dose with physician guidance
- Extended-release niacin + statins: Extended-release niacin carries hepatotoxicity risk; combined with statins, risk of myopathy and rhabdomyolysis is increased (Anderson et al. 2014). Avoid unless under strict medical supervision with liver function monitoring
- D-ribose + diabetes medications: Ribose can lower blood glucose; monitor closely and adjust hypoglycemic medication if needed.
- ALCAR + thyroid medication: L-carnitine inhibits thyroid hormone nuclear uptake in a dose-dependent manner (Benvenga et al. 2001); patients on thyroid replacement should consult their physician before supplementing L-carnitine and monitor thyroid function
Additional interactions.
- CoQ10 + antihypertensives: CoQ10 can lower blood pressure; combining with fludrocortisone or midodrine (common in ME/CFS for orthostatic intolerance) may require dose adjustment. Monitor blood pressure when initiating
- D-ribose + glucose monitoring: Some glucose meters can misread ribose as glucose, producing falsely elevated readings. Use ribose-compatible meters if monitoring blood glucose regularly
- Creatine + renal function monitoring: Creatine supplementation raises serum creatinine (a creatine metabolite), which can confound laboratory assessment of kidney function. Inform physicians of creatine use before renal panels; cystatin C is an alternative GFR marker unaffected by creatine intake
Timing conflicts.
- NADH requires an empty stomach (30–60 minutes before food); CoQ10 requires fat with meals. Take NADH first thing in the morning, CoQ10 with breakfast or lunch
- NAD+ precursors (NR, NMN) may have a mildly stimulating effect—avoid evening dosing if sleep-sensitive
- D-ribose should be taken with meals to prevent blood sugar dips
- ALCAR may cause insomnia or overstimulation; take split doses in the morning and early afternoon, not after 2–3 PM